Treatment of Liver Disease Ledipasvir (GS-5885) (CAS 1256388-51-8)

October 26, 2018

Model NO.: CAS: 1256388-51-8
Origin: China
HS Code: 3002909099
Model NO.: CAS: 1256388-51-8
Origin: China
HS Code: 3002909099
Treatment of liver disease Ledipasvir (GS-5885) (CAS 1256388-51-8) 

Basic info.

Product Name: Ledipasvir (GS-5885) 
Ledipasvir Synonyms: GS 5885;GS5885;GS-5885;Ledipasvir;GS-5885/Ledipasvir;gs-5885/gs5885;Ledipasvir / GS 5885;GS 588 
Ledipasvir CAS: 1256388-51-8 
Ledipasvir Purity:99%
Ledipasvir package:Well packaged

Additional info.

Ledipasvir trademark: Quanao
Ledipasvir origin: China
Ledipasvir HS code: 3002909099 
Ledipasvir production capacity: 200kg/month
Ledipasvir usage: Treatment of liver disease 

Product description

Treatment of liver disease Ledipasvir (GS-5885) (CAS 1256388-51-8)  

Product Name: Ledipasvir (GS-5885) 
Ledipasvir Synonyms: GS 5885;GS5885;GS-5885;Ledipasvir;GS-5885/Ledipasvir;gs-5885/gs5885;Ledipasvir / GS 5885;GS 588 
Ledipasvir CAS: 1256388-51-8 
Ledipasvir MF: C49H54F2N8O6 
Ledipasvir Molecular Weight: 889.0 
Ledipasvir Product Categories: API 
Ledipasvir Categories: NS5A inhibitors;Fluorenes;Carbamates;Benzimidazoles;Cyclopropanes;Imidazoles;Breakthrough therapy
Ledipasvir Purity : 98%
Ledipasvir Solubility DMSO 
Ledipasvir Storage at -20°C 
Ledipasvir Appearance : White powders 
Ledipasvir Package : 50g/foil bag
Ledipasvir Usage : Ledipasvir is most commonly used in combination with sofosbuvir for treatment in chronic hepatitis C genotype 1 patients. 
This drug has been tested and shown efficacy in treatment-naive and treatment experienced patients. 
 
Ledipasvir detail Description :
 
Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
 
Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.
 
Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the nucleotide analog inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1.The sofosbuvir/ledipasvir coformulation is being tested with and without ribavirin. In February 2014 Gilead has filed for United States Food and Drug Administration (FDA) approval of ledipasvir/sofosbuvir oral treatment, without interferon and ribavirin.
 
On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg called Harvoni.
 
Ledipasvir Application :
 
GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent suppression of genotype 1 HCV replicons. GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Ledipasvir (formerly GS-5885) is currently in Phase III clinical trials.

Ledipasvir Specification Sheet (COA):


Items		 Specifications Test Results Method
Appearance Off-white to light brown powder Light yellow powder Visual
Identification The retention time correspond to reference standard Conform HPLC
The IR spectrum correspond to reference standard Conform IR
Specific rotation -180.0°~-160.0° -169.5° USP<781>
Loss on drying NMT 0.5% 0.12% USP<731>
Residue on ignition NMT 0.2% 0.07% USP<281>
Heavy metal NMT 20ppm Conform USP<231>
Related substance Maximum individual impurity
: NMT 0.1%		 0.07% HPLC
Total impurities: NMT 1.0% 0.30% HPLC
Purity NLT 99.5% 99.7% HPLC


 
Packaging & Delivery Process:
 
1.Delivery Guarantee
   There are many kinds of express way to choose .We had 15 years of experience in this field .
2.Package
   Peptides and steroids would be packaged discreetly , it is enough to pass customs .
3.After-sales service                                                                                                                 We will offer you package photos after your payment , so that you can distinguish between products.
  Treatment of liver disease Ledipasvir (GS-5885) (CAS 1256388-51-8) 

Basic info.

Product Name: Ledipasvir (GS-5885) 
Ledipasvir Synonyms: GS 5885;GS5885;GS-5885;Ledipasvir;GS-5885/Ledipasvir;gs-5885/gs5885;Ledipasvir / GS 5885;GS 588 
Ledipasvir CAS: 1256388-51-8 
Ledipasvir Purity:99%
Ledipasvir package:Well packaged

Additional info.

Ledipasvir trademark: Quanao
Ledipasvir origin: China
Ledipasvir HS code: 3002909099 
Ledipasvir production capacity: 200kg/month
Ledipasvir usage: Treatment of liver disease 

Product description

Treatment of liver disease Ledipasvir (GS-5885) (CAS 1256388-51-8)  

Product Name: Ledipasvir (GS-5885) 
Ledipasvir Synonyms: GS 5885;GS5885;GS-5885;Ledipasvir;GS-5885/Ledipasvir;gs-5885/gs5885;Ledipasvir / GS 5885;GS 588 
Ledipasvir CAS: 1256388-51-8 
Ledipasvir MF: C49H54F2N8O6 
Ledipasvir Molecular Weight: 889.0 
Ledipasvir Product Categories: API 
Ledipasvir Categories: NS5A inhibitors;Fluorenes;Carbamates;Benzimidazoles;Cyclopropanes;Imidazoles;Breakthrough therapy
Ledipasvir Purity : 98%
Ledipasvir Solubility DMSO 
Ledipasvir Storage at -20°C 
Ledipasvir Appearance : White powders 
Ledipasvir Package : 50g/foil bag
Ledipasvir Usage : Ledipasvir is most commonly used in combination with sofosbuvir for treatment in chronic hepatitis C genotype 1 patients. 
This drug has been tested and shown efficacy in treatment-naive and treatment experienced patients. 
 
Ledipasvir detail Description :
 
Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
 
Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.
 
Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the nucleotide analog inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1.The sofosbuvir/ledipasvir coformulation is being tested with and without ribavirin. In February 2014 Gilead has filed for United States Food and Drug Administration (FDA) approval of ledipasvir/sofosbuvir oral treatment, without interferon and ribavirin.
 
On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg called Harvoni.
 
Ledipasvir Application :
 
GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent suppression of genotype 1 HCV replicons. GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Ledipasvir (formerly GS-5885) is currently in Phase III clinical trials.

Ledipasvir Specification Sheet (COA):


Items		 Specifications Test Results Method
Appearance Off-white to light brown powder Light yellow powder Visual
Identification The retention time correspond to reference standard Conform HPLC
The IR spectrum correspond to reference standard Conform IR
Specific rotation -180.0°~-160.0° -169.5° USP<781>
Loss on drying NMT 0.5% 0.12% USP<731>
Residue on ignition NMT 0.2% 0.07% USP<281>
Heavy metal NMT 20ppm Conform USP<231>
Related substance Maximum individual impurity
: NMT 0.1%		 0.07% HPLC
Total impurities: NMT 1.0% 0.30% HPLC
Purity NLT 99.5% 99.7% HPLC


 
Packaging & Delivery Process:
 
1.Delivery Guarantee
   There are many kinds of express way to choose .We had 15 years of experience in this field .
2.Package
   Peptides and steroids would be packaged discreetly , it is enough to pass customs .
3.After-sales service                                                                                                                 We will offer you package photos after your payment , so that you can distinguish between products.
Â